CepTor to Present at the White Mountain Capital Conference Today NEWPORT BEACH, Calif., April 19 /PRNewswire-FirstCall/ -- CepTor, Corp. (OTC:CEPO) (BULLETIN BOARD: CEPO) , CEO Bill Pursley will be presenting today at White Mountain Capital's Third Annual Biotechnology Conference, Tuesday April 19, 2005 at the Rihga Royal Hotel in Midtown, Manhattan. Mr. Pursley will be speaking on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases with emphasis on muscular dystrophy at 4pm in the Broadway Suite, Room 508. For more information or to register for the conference please visit: http://whitemountaincapital.com/ConferenceAd2005/ In an earlier company release today, the company announced that intellectual property filings have been made to further strengthen its patent position for the Company's muscle cell targeted protease inhibitor platform technology. About CepTor Corporation CepTor Corporation is a biopharmaceutical company focusing on the development of proprietary, cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases. The Company's mission is to increase the quality and quantity of life of people suffering with these diseases. CepTor's primary efforts are currently being focused on moving its lead product, MYODUR, into phase I/II clinical trials for Duchenne's muscular dystrophy. The Company's broad platform technology also includes the development of products for multiple sclerosis, retinal degeneration and epilepsy. CONTACTS: Don Fallon, CFO CepTor Corporation (410) 527-9998 Fax (410) 527-9867 Nicole Mittelstaedt Director of Communications InvestSource Inc. (949) 340-2716 This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement. DATASOURCE: CepTor Corporation CONTACT: Don Fallon, CFO of CepTor Corporation, +1-410-527-9998, fax, +1-410-527-9867; or Nicole Mittelstaedt, Director of Communications of InvestSource Inc., +1-949-340-2716, for CepTor Corporation Web site: http://whitemountaincapital.com/ConferenceAd2005

Copyright